Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

May 31, 2012

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

ALN-RSV01

Administered by nebulization once daily for 5 days

DRUG

Normal Saline

Administered by nebulization once daily for 5 days

Trial Locations (33)

1090

Clinical Site, Vienna

2010

Clinical Site, Darlinghurst

3004

Clinical Site, Melbourne

5000

Clinical Site, Adelaide

6001

Clinical Site, Perth

10032

Clinical Site, New York

10117

Clinical Site, Berlin

15213

Clinical Site, Pittsburgh

19104

Clinical Site, Philadelphia

20246

Clinical Site, Hamburg

30322

Clinical Site, Atlanta

30625

Clinical Site, Hanover

33606

Clinical Site, Tampa

37232

Clinical Site, Nashville

44195

Clinical Site, Cleveland

45239

Clinical Site, Essen

48109

Clinical Site, Ann Arbor

60153

Clinical Site, Chicago

60637

Clinical Site, Chicago

63110

Clinical Site, St Louis

66421

Clinical Site, Homburg/Saar

67091

Clinical Site, Strasbourg

75390

Clinical Site, Dallas

75908

Clinical Site, Paris

77030

Clinical Site, Houston

80202

Clinical Site, Denver

85013

Clinical Site, Phoenix

90033

Clinical Site, Los Angeles

02114

Clinical Site, Boston

02115

Clinical Site, Boston

T6G 2E1

Clinical Site, Edmonton

M5G 2N2

Clinical Site, Toronto

04103

Clinical Site, Leipzig

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY